These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 35589568)

  • 1. [Progress in research of 2019-nCoV Omicron variant].
    Huang Y; Li YH; Xie SL; Rong ZH; Li BS; Kang M; Deng AP; Li Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 May; 43(5):655-662. PubMed ID: 35589568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in research of epidemiologic feature and control of SARS-CoV-2 Delta variant].
    Du M; Liu M; Liu J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1774-1779. PubMed ID: 34814611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.
    Wang L; Cheng G
    J Med Virol; 2022 Apr; 94(4):1728-1733. PubMed ID: 34897752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa.
    Yu Y; Yu Y; Zhao S; He D
    Math Biosci Eng; 2022 Jul; 19(10):10361-10373. PubMed ID: 36031998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2022 Feb; 28():e936199. PubMed ID: 35102132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
    CDC COVID-19 Response Team
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in research of etiology and epidemiology of 2019-nCoV Omicron variant].
    Liao CX; Wang B; Lyu J; Li LM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Nov; 43(11):1691-1698. PubMed ID: 36444449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection.
    Wu Y; Long Y; Wang F; Liu W; Wang Y
    Immun Inflamm Dis; 2022 Dec; 10(12):e733. PubMed ID: 36444634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of transmissibility of 2019-nCoV Omicron variant in Beijing].
    Du J; Wang JM; Wang J; Gao YL; Pang XH; Li G
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Sep; 43(9):1364-1369. PubMed ID: 36117340
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa.
    Liu Y; Yu Y; Zhao Y; He D
    Int J Infect Dis; 2022 Jul; 120():146-149. PubMed ID: 35462038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion.
    Grabowski F; Kochańczyk M; Lipniacki T
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importation of SARS-CoV-2 Omicron variant in Beijing, China.
    Li F; Liang Z; Cui S; Lv B; Feng Z; Xu H; Jia L; Yang P; Wang Q; Pan Y; Zhang D
    Biosaf Health; 2022 Jun; 4(3):150-153. PubMed ID: 35463809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron: the highly mutational COVID-19 variant with immune escape.
    Khajotia R
    Pan Afr Med J; 2022; 41():84. PubMed ID: 35432693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hotspots for SARS-CoV-2 Omicron variant spread: Lessons from New York City.
    Ramírez JD; Castañeda S; Ballesteros N; Muñoz M; Hernández M; Banu R; Shrestha P; Chen F; Shi H; ; van Bakel H; Simon V; Cordon-Cardo C; Sordillo EM; Paniz-Mondolfi AE
    J Med Virol; 2022 Jul; 94(7):2911-2914. PubMed ID: 35243662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
    Saxena SK; Kumar S; Ansari S; Paweska JT; Maurya VK; Tripathi AK; Abdel-Moneim AS
    J Med Virol; 2022 Apr; 94(4):1738-1744. PubMed ID: 34905235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic?
    Ding K; Jiang W; Xiong C; Lei M
    Immun Inflamm Dis; 2022 Apr; 10(4):e606. PubMed ID: 35349754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-COV-2 Variants: Differences and Potential of Immune Evasion.
    Hirabara SM; Serdan TDA; Gorjao R; Masi LN; Pithon-Curi TC; Covas DT; Curi R; Durigon EL
    Front Cell Infect Microbiol; 2021; 11():781429. PubMed ID: 35118007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.
    Meo SA; Meo AS; Al-Jassir FF; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8012-8018. PubMed ID: 34982465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiological characteristics of two local COVID-19 outbreaks caused by 2019-nCoV Omicron variant in Guangzhou, China].
    Huang Y; Zheng ZW; Chen C; Li K; Chen SY; Chen YY; Jing QL; Ma Y; Luo L; Yang ZC; Zhang ZB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Nov; 43(11):1705-1710. PubMed ID: 36444451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.